LEASES: - Additional Information (Details)
|
|
1 Months Ended |
12 Months Ended |
|
|
Apr. 01, 2021
USD ($)
|
Sep. 30, 2021
USD ($)
|
Apr. 30, 2021
USD ($)
|
Mar. 31, 2021
USD ($)
item
|
Dec. 31, 2021
USD ($)
|
Dec. 31, 2020
USD ($)
|
Dec. 31, 2019
USD ($)
|
Jan. 31, 2021
m²
|
| Lessee, Operating Lease, Discount Rate |
|
|
|
|
9.80%
|
|
|
|
| Operating Lease, Payments |
|
|
|
|
$ 1,968,000
|
$ 937,000
|
$ 906,000
|
|
| Operating Lease, Weighted Average Remaining Lease Term |
|
|
|
|
14 years 3 months 18 days
|
4 years
|
|
|
| Security deposit |
|
|
|
|
$ 256,591
|
$ 125,892
|
|
|
| Right of use asset |
|
|
|
|
13,423,472
|
1,029,123
|
|
|
| Operating lease lability |
|
|
|
|
$ 13,821,509
|
1,029,123
|
|
|
| Twentieth Amendment To lease |
|
|
|
|
|
|
|
|
| Operating Lease, Expense |
|
|
$ 35,000
|
|
|
|
|
|
| Additional Operating Leases Rent Expense Net |
|
|
30,000
|
|
|
|
|
|
| Operating lease base rent for remaining space |
|
|
20,000
|
|
|
|
|
|
| Security deposit |
|
|
150,000
|
|
|
$ 54,000
|
|
|
| Monthly operating expenses |
|
|
11,000
|
|
|
|
|
|
| CytoSorbents Medical, Inc |
|
|
|
|
|
|
|
|
| Number of times lease renewal options available | item |
|
|
|
2
|
|
|
|
|
| Renewal term |
|
|
|
5 years
|
|
|
|
|
| Rent abatement term |
|
|
|
6 months
|
|
|
|
|
| CytoSorbents Europe GmbH |
|
|
|
|
|
|
|
|
| Area of Land | m² |
|
|
|
|
|
|
|
1,068
|
| Operating Lease, Expense |
$ 7,784
|
|
|
|
|
|
|
|
| Lease term |
5 years
|
|
|
|
|
|
|
|
| Other costs |
$ 239
|
|
|
|
|
|
|
|
| Right of use asset |
594,000
|
|
|
|
|
|
|
|
| Operating lease lability |
$ 594,000
|
|
|
|
|
|
|
|
| United States | CytoSorbents Medical, Inc |
|
|
|
|
|
|
|
|
| Lessee, Operating Lease, Discount Rate |
9.80%
|
|
|
|
|
|
|
|
| Remaining lease term |
|
|
|
15 years 6 months
|
|
|
|
|
| Annual rent expense increment rate |
|
|
|
2.75%
|
|
|
|
|
| Percentage of total building space occupied |
|
|
|
92.30%
|
|
|
|
|
| Allowance for building improvement |
|
|
|
$ 1,455,000
|
|
|
|
|
| Right of use asset |
$ 11,600,000
|
|
|
|
|
|
|
|
| Operating lease lability |
$ 11,600,000
|
|
|
|
|
|
|
|
| United States | Letter of credit | CytoSorbents Medical, Inc |
|
|
|
|
|
|
|
|
| Security Amount |
|
|
$ 1,334,000
|
|
|
|
|
|
| United States | Initial early term | CytoSorbents Medical, Inc |
|
|
|
|
|
|
|
|
| Operating Lease, Expense |
|
|
|
25,208
|
|
|
|
|
| United States | Early term | CytoSorbents Medical, Inc |
|
|
|
|
|
|
|
|
| Operating Lease, Expense |
|
|
|
88,254
|
|
|
|
|
| United States | First year of remaining lease term | CytoSorbents Medical, Inc |
|
|
|
|
|
|
|
|
| Operating Lease, Expense |
|
|
|
$ 111,171
|
|
|
|
|
| Germany |
|
|
|
|
|
|
|
|
| Operating Lease, Expense |
|
$ 12,100
|
|
|
|
|
|
|
| Additional Operating Leases Rent Expense Net |
|
$ 3,000
|
|
|
|
|
|
|